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Introduction
Cluster headache (CH) is a painful and debilitating disor-
der for which non-invasive vagus nerve stimulation
(nVNS) may be a treatment option.
Aim
Compare the efficacy of gammaCore®, a handheld
nVNS device, with the standard of care (SoC) in chronic
CH subjects in the randomized phase of the Prevention
and Acute (PREVA) Treatment of Chronic Cluster
Headache study.
Methods
PREVA was a multicenter study comprised of 3 phases: 2-
week run-in, 4-week randomized (1:1; nVNS vs SoC), and
4-week extension. Subjects randomized to nVNS delivered
stimulations prophylactically twice daily (mandatory) and
optionally for the rescue treatment of CH attack. The pri-
mary efficacy end point was the reduction in number of
CH attacks/week during the last 2 weeks of the rando-
mized phase versus the run-in phase. Additional end
points included the proportion of subjects with > 50%
reduction in CH attacks/week (response rate) and rescue
medication use; safety was assessed by monitoring the fre-
quency of adverse events.
Results
Ninety-seven subjects were randomized; data from 93
subjects (n = 45 nVNS; n = 48 SoC) were included in the
intention-to-treat population. Number of CH attacks/
week was significantly reduced in subjects treated with
nVNS compared with patients treated with SoC only (-7.6
vs -2.0; P = .002). Further, significantly more nVNS- than
SoC-treated subjects were considered treatment respon-
ders (34.4% vs 7.1%; P = .003). nVNS was associated with
less use of rescue medications and demonstrated a favor-
able safety/tolerability profile.
Conclusion
Prophylactic treatment of chronic CH with nVNS is safe
and, compared with SoC, reduces frequency of CH
attacks/week. Sham-controlled studies are warranted and
underway to confirm these data.
Abstract submitted on behalf of the PREVA Study
Investigators.
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